

Tara O'Donohue, M.D., M.S.
OdonohuT@mskcc.org

Current Position

Special Fellow/Clinical Instructor, Department of Pediatric Hematology/Oncology Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY	2020 – Present
Diplomate, American Board of Pediatrics	10/20/16 – 12/16/21
State Medical License: New York	6/26/16 – 12/31/21
Pediatric Hematology/Oncology Board Eligible	Spring 2021

Education and Post-Graduate Training

Chief Fellow, Department of Pediatric Hematology/Oncology Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY New York Presbyterian Hospital – Weill Cornell Medical Center (NYP-WCMC), New York, NY	2019 – 2020
Master's Degree in Clinical and Translational Investigation Weill Cornell Medicine Clinical and Translational Science Center, New York, NY	2018 – 2020
Fellow, Department of Pediatric Hematology/Oncology Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY New York Presbyterian Hospital – Weill Cornell Medical Center (NYP-WCMC), New York, NY	2017 – 2020
Chief Residency, Pediatrics, NYP-WCMC, New York, NY	2016 – 2017
Residency, Pediatrics, NYP-WCMC, New York, NY	2014 – 2016
Internship, Pediatrics, NYP-WCMC, New York, NY	2013 – 2014
M.D, Rutgers – Robert Wood Johnson Medical School (RWJMS), New Brunswick, New Jersey	2009 – 2013
B.A. in Psychology (Magna Cum Laude), Boston University Boston, Massachusetts	2005 – 2009

Honors and Awards

Kristen Ann Carr Fellow	2019
Betty Neuwirth Lee Fellow	2018
The James Horowitz Chief Resident of the Year Award, NYP-WCMC	2017
Pediatric Housestaff Award in Clinical Excellence, NYP-WCMC	2016
Pediatric Trainee Research Night, Oral Presentation 1 st Runner Up (NY Academy of Medicine)	2016
The Bruce Fisher Award, Rutgers – RWJMS	2013
The Artiss L. Powell, Jr. MD Memorial Scholarship, Rutgers – RWJMS	2013
Glasgow-Rubin Certificate of Commendation for Academic Achievement, Rutgers – RWJMS	2013
Scarlet Key Recipient, Boston University	2009
Student Organization of the Year – Global Medical Brigades (Founder), Boston University	2008

Memberships

Member, American Society of Clinical Oncology	2017
Member, American Society of Pediatric Hematology/Oncology	2017
Member, American Society of Hematology	2016
Member, Alpha Omega Alpha	2013
Member, Arnold P. Gold Humanism Honor Society	2013
Member, American Academy of Pediatrics	2013

Research

Evaluation of a Novel *ALK/ROS1/NTRK* Inhibitor in Pediatric Patient Derived Xenografts (PDXs) 2018 – Present

Evaluating the anti-tumor effect and pharmacodynamics of TPX-0005, a novel small molecule tyrosine kinase inhibitor, in pediatric PDX models of solid tumors and partnering with industry sponsor to translate preclinical findings into a first in pediatrics Phase 1/2 trial.

Mentors: Dr. Andrew Kung, Dr. Filemon Dela Cruz, Dr. Stephen Roberts, Dr. Julia Glade Bender

Accomplishment: Co-Principal Investigator, IRB approved, open to accrual (4/2020)

Differential Impact of *ALK* Mutations in Neuroblastoma 2018 – Present

Conducting a retrospective review of *ALK*-mutated pediatric neuroblastoma patients treated at MSKCC to characterize the landscape of frequency, type, and prognostic implications of *ALK* mutations.

Mentor: Dr. Shakeel Modak

Accomplishments: Manuscript in preparation, poster presentation SIOP 2019

Examining Outcomes of Adults and Children with Primary Mediastinal B-cell Lymphoma Treated with Dose-Adjusted EPOCH-R 2016 – 2017

Conducted a multi-center retrospective analysis of children and adults with primary mediastinal B-cell lymphoma treated with the dose adjusted EPOCH-R regimen across 24 academic centers.

Mentor: Dr. Lisa Giulino-Roth, NYP-WCMC, New York, NY

Accomplishment: Second Author Manuscript

Examining Outcomes of Children and Adolescents with Relapsed Hodgkin Lymphoma Treated with High Dose Therapy and Autologous Stem Cell Transplantation 2015 – 2017

Conducted a retrospective study examining prognostic factors of patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.

Mentor: Dr. Lisa Giulino-Roth

Accomplishment: Co-First Author Manuscript

Grants & Awards

Swim Across America Young Investigator Award 1/1/20-12/31/20

Title: Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib (TPX-0005) in Combination with Chemotherapy in Pediatric and Young Adult Subjects with Advanced or Metastatic Solid Tumors and Primary Central Nervous System Tumors

Amount: \$85,750

Role: Principal Investigator

Teaching

“A Randomized Trial of the Effectiveness of the Neutropenic Diet Versus Food Safety Guidelines on Infection Rate in Pediatric Oncology Patients” October 2018

Journal club presentation to pediatric hematology/oncology fellowship program

MSKCC, New York, NY

“Pediatric Aplastic Anemia” November 2017
Case presentation to pediatric hematology/oncology fellowship program with a focus on critical review of supporting medical literature for use of eltrombopag in this patient population.
MSKCC, New York, NY

“Bleeding in the Neonate” September 2017
Case presentation to residents and medical students which discussed differential and pathophysiology of thrombocytopenia in the neonatal population.
NYP-WCMC, New York, NY

Pediatric Housestaff Conference Presentations 2016 – 2017
As a chief resident, provided interactive morning reports twice weekly on general pediatric topics for residents and medical students.
NYP-WCMC, New York, NY

Other Institutional Activities

Pediatric Steering Committee 2020 – Present
Department of Pediatrics
MSKCC, New York, NY

Development of Tyrosine Kinase Inhibitor Long-Term Monitoring Guidelines January 2020
Pediatric Leukemia/Lymphoma Service
MSKCC, New York, NY

Graduate Medical Education Committee 2018 – Present
MSKCC, New York, NY

Quality Improvement Project- Department of Pediatrics 2018 – Present
Participated in optimizing after hours telephone triage systems to promote patient safety and enhance parent/patient satisfaction and access to critical resources.
MSKCC, New York, NY

Quality Improvement Project- Dept. of Pediatrics/Dept. of Laboratory Medicine 2016 – 2017
Participated in streamlining the lab ordering process for send-out samples by conducting intradepartmental surveys, engaging leadership in various laboratory medicine departments, and surveying housestaff to understand workflow and barriers to efficient and effective patient care.
NYP-WCMC, New York, NY

Quality Improvement Projects- Pediatric Resident Group Practice 2013 – 2017
Projects included improving overall rates of laboratory follow up and creating standardized handouts related to evaluation, diagnosis and treatment of iron deficiency anemia.
NYP-WCMC, New York, NY

Publications

Peer-Reviewed Articles

1. Giulino Roth L*, O'Donohue T*, Chen Z, Trippett T, Klein E, Kernan N, Kobos R, Prockop S, Scaradavou A, Shukla N, Steinherz P, Moskowitz A, Moskowitz C, and Boulad F. “Outcome of Children and Adolescents with Relapsed Hodgkin Lymphoma Treated with High Dose Therapy and Autologous Stem Cell Transplantation: A Memorial Sloan Kettering Experience.” *Leukemia and Lymphoma*. 2018 Aug;59(8):1861-1870. DOI: 10.1080/10428194.2017.1403601

2. Giulino Roth L, **O'Donohue T**, Chen Z, Bartlett N, LaCasce A, Martin-Doyle W, Barth M, Davies K, Blum K, Christian B, Casulo, C, Smith S, Godfrey J, Termuhlen A, Oberley M, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens D, Zeitler W, Forlenza C, Levine J, Williams M, Sima J, Bollard C, and Leonard J. "Outcomes of Adults and Children with Primary Mediastinal B-cell Lymphoma Treated with Dose-Adjusted EPOCH-R." *British Journal of Hematology*. 2017 Dec; 179(5):739-747. DOI: 10.1111/bjh.1451

Presentations

1. **O'Donohue T**, Ibañez G, Mauguen A, Siddiquee A, Rosales N, Calder P, Ndengu A, You D, Roberts SS, Dela Cruz F, and Kung AL. "Repotrectinib (TPX-0005) a next-generation ALK/ROS1/TRK inhibitor, has potent antiproliferative and anti-tumor activity as monotherapy and in combination with chemotherapy in neuroblastoma cell lines and pediatric patient derived xenograft models." Poster presented at EORTC-NCI-AACR Symposium: Molecular Targets and Cancer Therapeutics, October 24th, 2020 (Virtual).
2. **O'Donohue T**, Gulati N, Shukla N, Mauguen A, Kushner B, Cheung N, Roberts S, Basu E, and Modak S. Differential Impact of ALK Mutations in Neuroblastoma. Poster presented at Société Internationale d'Oncologie Pédiatrique (SIOP) Meeting, October 24th 2019, Lyon, France.